Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $137.00 price target on the stock.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer [Yahoo! Finance]
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer